Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: A Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481)

Peter H. Wiernik, Traci Leong, Martin M. Oken, Richard S. Neiman, Thomas M. Habermann, John M. Bennett, Stephen Schuster, John H. Glick

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses. Twenty-five patients (76%; 95% CI=55.6–87.1%) achieved a complete remission, the median duration of which cannot yet be determined, but the probability of remaining in continuous complete remission at 10 years is 64. The median survival from entry on this study for all evaluable patients is 10 years, and 12 patients were alive at the time of this analysis with a median follow-up for them of 15.5 years. Of the 22 patients who died, 11 died of progressive or recurrent Hodgkin's disease and 11 died of other causes including 7 second primary neoplasms and at least one myocardial infarction. Both are now well known late complications of Hodgkin's disease treatment.

Original languageEnglish (US)
Pages (from-to)357-363
Number of pages7
JournalLeukemia and Lymphoma
Volume40
Issue number42067
DOIs
StatePublished - Jan 1 2001

Keywords

  • Hodgkin's disease
  • chemotherapy
  • second neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: A Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481)'. Together they form a unique fingerprint.

  • Cite this